[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019108021A3 - 토파시티닙을 포함하는 약제학적 조성물 - Google Patents

토파시티닙을 포함하는 약제학적 조성물 Download PDF

Info

Publication number
WO2019108021A3
WO2019108021A3 PCT/KR2018/015103 KR2018015103W WO2019108021A3 WO 2019108021 A3 WO2019108021 A3 WO 2019108021A3 KR 2018015103 W KR2018015103 W KR 2018015103W WO 2019108021 A3 WO2019108021 A3 WO 2019108021A3
Authority
WO
WIPO (PCT)
Prior art keywords
tofacitinib
pharmaceutical composition
provides
present
water
Prior art date
Application number
PCT/KR2018/015103
Other languages
English (en)
French (fr)
Other versions
WO2019108021A2 (ko
Inventor
김진환
신동철
황용연
Original Assignee
보령제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보령제약 주식회사 filed Critical 보령제약 주식회사
Publication of WO2019108021A2 publication Critical patent/WO2019108021A2/ko
Publication of WO2019108021A3 publication Critical patent/WO2019108021A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 토파시티닙 또는 이의 약학적으로 허용되는 염을 함유하는 코어; 및 상기 코어 상에 수불용성 코팅기제 및 수용성 코팅기제를 함유하는 코팅층을 포함하는 약제학적 조성물에 대한 것이다. 본 발명은 토파시티닙의 초기 방출이 억제되고, 초반 지연 시간(Lag time)을 가지는 약제학적 조성물을 제공하며, 토파시티닙의 유효 혈중농도를 유지시켜 1일 1회 복용이 가능한 약제학적 조성물을 제공한다. 또한, 본 발명은 토파시티닙의 함량균일성, 가용성, 안정성 및 생체이용률이 우수한 약제학적 조성물을 제공한다.
PCT/KR2018/015103 2017-11-30 2018-11-30 토파시티닙을 포함하는 약제학적 조성물 WO2019108021A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170163608A KR102078805B1 (ko) 2017-11-30 2017-11-30 토파시티닙을 포함하는 약제학적 조성물
KR10-2017-0163608 2017-11-30

Publications (2)

Publication Number Publication Date
WO2019108021A2 WO2019108021A2 (ko) 2019-06-06
WO2019108021A3 true WO2019108021A3 (ko) 2019-07-25

Family

ID=66664069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015103 WO2019108021A2 (ko) 2017-11-30 2018-11-30 토파시티닙을 포함하는 약제학적 조성물

Country Status (2)

Country Link
KR (1) KR102078805B1 (ko)
WO (1) WO2019108021A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021451A1 (en) * 2019-08-29 2022-07-06 Synthon B.V. Controlled release tofacitinib compositions
CN110787145B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN111184696A (zh) * 2020-02-26 2020-05-22 江苏艾立康药业股份有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN112755000A (zh) * 2021-01-21 2021-05-07 石药集团欧意药业有限公司 一种枸橼酸托法替布缓释片

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130132630A (ko) * 2011-04-08 2013-12-04 화이자 인코포레이티드 토파시티닙의 결정질 형태 및 비결정질 형태, 및 토파시티닙 및 침투 증진제를 포함하는 제약 조성물
KR20130142168A (ko) * 2011-01-27 2013-12-27 라티오팜 게엠베하 조정된 방출을 위한 타소시티닙 함유 경구투여용 제제
KR20150131238A (ko) * 2013-03-16 2015-11-24 화이자 인코포레이티드 토파시티닙 경구용 지속 방출 투여 형태

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130142168A (ko) * 2011-01-27 2013-12-27 라티오팜 게엠베하 조정된 방출을 위한 타소시티닙 함유 경구투여용 제제
KR20130132630A (ko) * 2011-04-08 2013-12-04 화이자 인코포레이티드 토파시티닙의 결정질 형태 및 비결정질 형태, 및 토파시티닙 및 침투 증진제를 포함하는 제약 조성물
KR20150131238A (ko) * 2013-03-16 2015-11-24 화이자 인코포레이티드 토파시티닙 경구용 지속 방출 투여 형태

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURMESTER, G. R.: "Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial", THE LANCET, vol. 381, 2013, pages 451 - 460, XP002727328, doi:10.1016/S0140-6736(12)61424-X *
CADA, D. J.: "Tofacitinib", HOSPITAL PHARMACY, vol. 48, no. 5, 2013, pages 413 - 424 *

Also Published As

Publication number Publication date
KR20190064215A (ko) 2019-06-10
WO2019108021A2 (ko) 2019-06-06
KR102078805B1 (ko) 2020-02-19

Similar Documents

Publication Publication Date Title
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
PH12020500068A1 (en) Preparation comprising vonoprazan
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
WO2013129889A9 (ko) 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
WO2016142708A3 (en) Pharmaceutical composition
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
PH12019500919A1 (en) Esomeprazole~containing complex capsule and preparation method therefor
EP3216450A8 (en) Pharmaceutical preparation comprising cyclin inhibitor and preparation method thereof
WO2018085495A3 (en) Dissolvable films and methods of their use
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
EP3648745A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
EP3898582A4 (en) NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2022000297A (es) Formulacion de naltrexona.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18882917

Country of ref document: EP

Kind code of ref document: A2